Pfizer (PFE) on Wednesday announced that it has begun a Phase 3 trial for its 25-valent pneumococcal vaccine, PF-07872412 (25vPnC), for infants after the shot outperformed its pneumococcal 20-valent ...

Success rates in phase II and phase III clinical trials are recognized as two of the most powerful drivers of overall efficiency in drug development (Nat. Rev. Drug Discov. 23, 656–657; 2024). With ...

Eli Lilly on Thursday released results from TRIUMPH-1, its pivotal Phase 3 trial for the experimental obesity drug ...

Ultragenyx and Mereo Biopharma are expecting to report results from two phase 3 trials for Osteogenesis Imperfecta (OI), commonly known as brittle bone disease, at the end of 2025. Earlier in July, ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) ...

The trial assesses Precem-TcT efficacy and safety alone or with bevacizumab in mCRC patients after previous therapies.

Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of ...

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Vitiligo Trial to Initiate in Mid-2026 Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of EB06, its ...

Last Patient Evaluation Visit Completed with Topline Data Release Targeted Q3-2026 CARSON CITY, Nev., May 18, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie” or the "Company”), a ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke, preeclampsia and fetal growth restriction, ...